A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma [clinicaltrials:NCT01353482]
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma [clinicaltrials:NCT01353482]
Bio2RDF identifier
NCT01353482
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT01353482
identifiers.org URI
acronym [clinicaltrials_vocabulary:acronym]
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
Mesothelioma is a relat ...... ostat
to the treatment.
brief title [clinicaltrials_vocabulary:brief-title]
A Phase I/II Study of First Li ...... Malignant Pleural Mesothelioma
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
detailed description [clinicaltrials_vocabulary:detailed-description]
Mesothelioma is a rapid ...... :1 to the two treatment arms.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2011-05-11T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
mesothelioma
vorinostat
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-03-21T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
nct id [clinicaltrials_vocabulary:nct-id]
NCT01353482
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Phase I/II Study of First Li ...... Malignant Pleural Mesothelioma
org study id [clinicaltrials_vocabulary:org-study-id]
UCL/08/0359
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
2009-013638-26
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-03-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
UCL CTC were informed by Merck ...... another trial with trial drug.
identifier
clinicaltrials:NCT01353482
title
A Phase I/II Study of First Li ...... Malignant Pleural Mesothelioma
@en
type
label
A Phase I/II Study of First Li ...... a [clinicaltrials:NCT01353482]
@en